In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Dynavax Technologies Corp.. Trade Record

NASDAQ:DVAX Dynavax Technologies Corp. stock gains 19.78% Exit Sep 26, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart DVAX Aug 30, 2017, priceSeries
About Dynavax Technologies Corp.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
91.28
Entry Date
Aug 30, 2017
Entry Price
17.20
Sell Date
Sep 26, 2017
Sell Price
20.60
Net Gain
19.78%
Hold Time
18 Trading Days